Latest Insider Transactions at Arcutis Biotherapeutics, Inc. (ARQT)
This section provides a real-time view of insider transactions for Arcutis Biotherapeutics, Inc. (ARQT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Arcutis Biotherapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Arcutis Biotherapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 03
2021
|
Todd Franklin Watanabe Director |
BUY
Grant, award, or other acquisition
|
Direct |
32,700
+5.18%
|
-
|
Mar 02
2021
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
2,107
-0.37%
|
$73,745
$35.19 P/Share
|
Mar 01
2021
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
2,200
-0.53%
|
$74,800
$34.61 P/Share
|
Mar 01
2021
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+0.35%
|
$6,600
$3.29 P/Share
|
Mar 01
2021
|
Kenneth A. Lock Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
933
-4.04%
|
$31,722
$34.2 P/Share
|
Mar 01
2021
|
John W Smither Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
773
-3.07%
|
$26,282
$34.2 P/Share
|
Mar 01
2021
|
Patricia A. Turney SVP, Operations |
SELL
Open market or private sale
|
Direct |
934
-9.15%
|
$31,756
$34.52 P/Share
|
Mar 01
2021
|
David W Osborne Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
780
-0.33%
|
$26,520
$34.57 P/Share
|
Feb 22
2021
|
Bhaskar Chaudhuri Director |
SELL
Open market or private sale
|
Direct |
10,000
-0.56%
|
$350,000
$35.66 P/Share
|
Feb 16
2021
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,654
+0.43%
|
$2,654
$1.31 P/Share
|
Feb 10
2021
|
John W Smither Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
2,000
-2.22%
|
$70,000
$35.64 P/Share
|
Feb 10
2021
|
John W Smither Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
750
-2.89%
|
$26,250
$35.64 P/Share
|
Feb 10
2021
|
John W Smither Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
750
+2.81%
|
$750
$1.68 P/Share
|
Feb 05
2021
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
10,000
-0.87%
|
$340,000
$34.13 P/Share
|
Feb 05
2021
|
Todd Franklin Watanabe Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+1.7%
|
$10,000
$1.68 P/Share
|
Feb 04
2021
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
19,861
+4.58%
|
$19,861
$1.68 P/Share
|
Feb 01
2021
|
John W Smither Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
3,750
-4.0%
|
$131,250
$35.0 P/Share
|
Feb 01
2021
|
John W Smither Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,250
-4.73%
|
$43,750
$35.0 P/Share
|
Feb 01
2021
|
John W Smither Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+4.51%
|
$1,250
$1.68 P/Share
|
Feb 01
2021
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
2,200
-0.3%
|
$74,800
$34.74 P/Share
|
Feb 01
2021
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+0.59%
|
$2,200
$1.68 P/Share
|
Feb 01
2021
|
Bhaskar Chaudhuri Director |
SELL
Open market or private sale
|
Direct |
9,949
-1.1%
|
$328,317
$33.25 P/Share
|
Jan 29
2021
|
Bhaskar Chaudhuri Director |
SELL
Open market or private sale
|
Direct |
51
-0.01%
|
$1,377
$27.5 P/Share
|
Jan 19
2021
|
John W Smither Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
1,250
-1.32%
|
$37,500
$30.0 P/Share
|
Jan 19
2021
|
John W Smither Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
500
-1.95%
|
$15,000
$30.0 P/Share
|
Jan 19
2021
|
John W Smither Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+1.91%
|
$500
$1.68 P/Share
|
Jan 12
2021
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,222
+0.66%
|
$0
$0.58 P/Share
|
Jan 04
2021
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
2,200
-1.2%
|
$59,400
$27.82 P/Share
|
Jan 04
2021
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+0.59%
|
$2,200
$1.68 P/Share
|
Dec 14
2020
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,222
+0.67%
|
$0
$0.58 P/Share
|
Dec 14
2020
|
John W Smither Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
3,750
-3.8%
|
$112,500
$30.0 P/Share
|
Dec 14
2020
|
John W Smither Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,500
-5.62%
|
$45,000
$30.0 P/Share
|
Dec 14
2020
|
John W Smither Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+5.32%
|
$1,500
$1.68 P/Share
|
Dec 14
2020
|
David W Osborne Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-5.65%
|
$450,000
$30.0 P/Share
|
Dec 01
2020
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
2,200
-0.4%
|
$57,200
$26.28 P/Share
|
Dec 01
2020
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+0.6%
|
$2,200
$1.68 P/Share
|
Nov 12
2020
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,222
+0.67%
|
$0
$0.58 P/Share
|
Nov 02
2020
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
2,200
-1.22%
|
$39,600
$18.27 P/Share
|
Nov 02
2020
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+0.6%
|
$2,200
$1.68 P/Share
|
Oct 26
2020
|
Kenneth A. Lock Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,668
+10.88%
|
$16,008
$6.52 P/Share
|
Oct 22
2020
|
Kenneth A. Lock Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,695
+12.31%
|
$16,170
$6.52 P/Share
|
Oct 15
2020
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,222
+0.68%
|
$0
$0.58 P/Share
|
Oct 15
2020
|
Kenneth A. Lock Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+31.25%
|
$45,000
$6.52 P/Share
|
Oct 02
2020
|
Jonathan Silverstein Director |
BUY
Open market or private purchase
|
Indirect |
496,000
+14.59%
|
$12,400,000
$25.0 P/Share
|
Oct 02
2020
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
496,000
+14.59%
|
$12,400,000
$25.0 P/Share
|
Oct 01
2020
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
2,200
-0.61%
|
$57,200
$26.68 P/Share
|
Oct 01
2020
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+0.61%
|
$2,200
$1.68 P/Share
|
Sep 29
2020
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
6,000
-0.53%
|
$180,000
$30.0 P/Share
|
Sep 29
2020
|
Todd Franklin Watanabe Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+0.52%
|
$6,000
$1.68 P/Share
|
Sep 29
2020
|
John W Smither Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
1,250
-1.25%
|
$37,500
$30.0 P/Share
|